The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
CRA's Competition & Antitrust Practice commemorates Canada Day
Our Toronto team advises clients on complex antitrust, merger, and regulatory matters in Canada, Europe, and the United States. We would like to take this...